Home pageBIOCON • NSE
add
Biocon Ltd
Chiusura precedente
364,45 ₹
Intervallo giornaliero
366,50 ₹ - 373,65 ₹
Intervallo annuale
244,55 ₹ - 404,70 ₹
Cap di mercato
446,41 Mld INR
Volume medio
5,56 Mln
Rapporto P/E
55,43
Dividendo/Prezzo
0,13%
Borsa valori principale
NSE
Notizie
Dati finanziari
Conto economico
Entrate
Utile netto
| (INR) | dic 2024info | Variazione Y/Y |
|---|---|---|
Entrate | 38,56 Mld | -2,47% |
Spese di gestione | 21,36 Mld | -3,34% |
Utile netto | 251,00 Mln | -96,20% |
Margine di profitto netto | 0,65 | -96,11% |
Utili per azione | 0,13 | -97,54% |
EBITDA | 7,42 Mld | -5,55% |
Aliquota fiscale effettiva | 47,98% | — |
Stato patrimoniale
Totale attivo
Totale passivo
| (INR) | dic 2024info | Variazione Y/Y |
|---|---|---|
Investimenti cash/breve termine | — | — |
Totale attivo | — | — |
Totale passivo | — | — |
Patrimonio netto totale | — | — |
Azioni in circolazione | 1,20 Mld | — |
Prezzo/valore contabile | — | — |
Redditività dell'attivo | — | — |
Rendimento sul capitale | 2,08% | — |
Flusso di cassa
Flusso di cassa netto
| (INR) | dic 2024info | Variazione Y/Y |
|---|---|---|
Utile netto | 251,00 Mln | -96,20% |
Liquidità di esercizio | — | — |
Contanti da investimenti | — | — |
Contanti da finanziamenti | — | — |
Flusso di cassa netto | — | — |
Flusso di cassa libero | — | — |
Informazioni
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.
Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA.
Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
Fondazione
1978
Sito web
Dipendenti
16.315
